Disruption of Hypothalamic Regulation of Appetite **Associated with Proton Beam Therapy**



Aashish Sethi¹, Mohammed Didi¹, Conor Mallucci², Nicola Thorp³, James Hayden⁴, Barry Pizer³, Lisa Howell³, **Joanne Blair**¹ Departments of Endocrinology¹, Neurosurgery², Clinical Oncology³ and Radiology⁴ Alder Hey Children's Hospital, Liverpool,

Introduction

> Proton beam therapy (PBT) is being used increasingly for the treatment of craniopharyngioma because radiation dose to the temporal lobe, the hypothalamus and the optic apparatus is reduced. This is perceived as a major benefit; however its real therapeutic gain has yet to be established².

> We are report two patients diagnosed with craniopharyngioma, treated with PBT, who and presented with profound anorexia and weight loss following irradiation.

Case 1

- > A 12 year old girl presented with history of headache, generalised tonic-clonic seizure
- MRI revealed obstructive hydrocephalus and posterior fossa tumor
- > Hydrocephalus was drained and an ommaya reservoir was inserted
- > A near total resection of the craniopharyngioma was performed leaving minimal tumor adherent to the posterior cerebral artery and hypothalamus.
- > Assessment of pituitary function following surgery demonstrated panhypopituitarism, including diabetes insipidus.
- > 4 months following surgery, she received PBT (50.44CGE in 28 daily fractions)
- > She became anorexic with weight loss (BMI SDS decrease by 1.84) (Figure 1).
- > Over period of years developed excessive eating and obesity requiring intervention.

> After vigorous monitoring and continuous active intervention she gained weight

-10 admission Before 1st | Before 2nd Recent Before PBT (after ~8 After 1 Year After 2 Year After 3 Year Surgery weight weeks of PBT) —Weight (Kg) 40.6 26.6 37.5 58.6 63.9 76.9 0.64 —Weight (SD) 0.55 -0.27 -2.11 -1.5 0.45 0.82 2.07 -BMI(Kg/m2)22.8 19.7 27.3 26.9 30.2 —BMI (SD) 1.58 1.47 0.52 -3.47 -0.61 2.11 1.89 1.66

Case 2

- > A 4 year old boy with short stature was diagnosed with growth hormone deficiency.
- MRI revealed a suprasellar tumour.
- > A subtotal resection removed all tumor except small layer at pituitary stalk and base of hypothalamus. Histology confirmed craniopharyngioma
- > Assessment of pituitary function following surgery demonstrated panhypopituitarism, including diabetes insipidus.
- Four months following surgery MRI revealed a moderate-size cyst, which was fenestrated and an ommaya reservoir was inserted
- > Eleven months later he received PBT (54 CGE in 30 daily fractions)
- > Following PBT there was an abrupt onset of anorexia.
- \triangleright and BMI decreased \simeq 2SD, requiring supported nutrition by gastrostomy.
- > One year following PBT, appetite recovered and gastrostomy was removed.




Figure 1: Serial weight and BMI of case 1

Figure 2: Serial weight and BMI of case 2

Discussion

- > The most recent advances in the treatment of craniopharyngioma, including precision radiotherapy, focus on minimizing treatment-related toxicity.
- Cranial irradiation is a leading cause of hypothalamic and pituitary injury. The hypothalamus has a critical role in energy homeostasis, which is regulated by a complex neuroendocrine system. Injury to the hypothalamus can lead to anorexia, weight loss or obesity³.
- > A proton has a defined maximum penetration depth, called the Bragg peak, at which the majority of its energy is released over a few millimeters beyond which it has no energy⁴ and early clinical results report good favorable clinical outcomes.
- > A relative low rate of hypothalamic dysfunction has been described associated with PBT as compare to conventional radiotherapy. However, a recent study shows an association of radiation dose with hypothalamic and pituitary damage⁵.

Conclusion

- > Although PBT is generally well-tolerated for the treatment for craniopharyngioma, long-term follow up and larger cohort studies are necessary to establish whether dosimetric advantages of PBT translates to clinical benefits in in reducing long-term toxicity
- > Hypothalamic involvement of craniopharyngioma and treatment-related lesions of hypothalamic areas are major risk factors for impaired survival, neuropsychological deficits.
- > Any patient receiving PBT/conventional radiotherapy should be followed up for acute and long term sequalae of radiation.
- > Until further data regarding the long term outcomes of PBT treated patients are available, we suggest surveillance should be based on radiation dose, rather than the modality of radiation delivery.

References:

- 1. Conroy R, Gomes L, Owen C, Buchsbaum J, Ahern V. Clinical equipoise: protons and the child with craniopharyngioma. J Med Imag Radiat Oncol 2015;59(3):379e385.
- 2. Boehling NS, Grosshans DR, Bluett JB, Palmer MT, Song X, Amos RA, et al. Dosimetric comparison of three-dimensional conformal proton radiotherapy, intensity-modulated proton therapy, and intensity-modulated radiotherapy for treatment of pediatric craniopharyngiomas. Int J Radiat Oncol Biol Phys 2012;82(2):643e652.
- 3. Müller, H. L. (2016). Craniopharyngioma and hypothalamic injury. Current Opinion in Endocrinology & Diabetes and Obesity, 23(1), 81–89. doi:10.1097/med.000000000000214
- 4. [No authors listed.] Prescribing, reporting and recording proton beam therapy. J ICRU 7, NP (2007).
- 5. Vatner RE, Niemierko A, Misra M, et al. Endocrine deficiency as a function of radiation dose to the hypothalamus and pituitary in pediatric and young adult patients with brain tumors. J Clin Oncol. 2018;36(28):2854-2862

Acknowledgement: The presented work resulted from collaboration made possible through the Merck sponsored educational programme "ESPE Clinical Fellowship".

Conflict of Interest: The authors have no real or perceived conflicts of interest in any matters, including financial issues, relating to this work.





